pregabalin + placebo + pramipexole
Phase 3Completed 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Restless Legs Syndrome
Conditions
Restless Legs Syndrome
Trial Timeline
Dec 1, 2009 → Jun 1, 2011
NCT ID
NCT00991276About pregabalin + placebo + pramipexole
pregabalin + placebo + pramipexole is a phase 3 stage product being developed by Pfizer for Restless Legs Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT00991276. Target conditions include Restless Legs Syndrome.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00991276 | Phase 3 | Completed |
Competing Products
20 competing products in Restless Legs Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Gabapentin enacarbil | Astellas Pharma | Approved | 85 |
| ASP8825 | Astellas Pharma | Phase 3 | 77 |
| Regnite | Astellas Pharma | Pre-clinical | 23 |
| ASP8825 + Placebo | Astellas Pharma | Phase 2 | 52 |
| Placebo + Gabapentin enacarbil | Astellas Pharma | Approved | 85 |
| Apomorphine Sublingual Film + Placebo | Sumitomo Pharma | Approved | 85 |
| Suvorexant | Merck | Approved | 85 |
| Cabergoline | Pfizer | Phase 3 | 76 |
| Placebo + pregabalin + pregabalin | Pfizer | Phase 3 | 76 |
| placebo + Pregabalin + Pregabalin + Pregabalin + Pregabalin + Pregabalin | Pfizer | Phase 2 | 51 |
| placebo and pregabalin + pramipexol + pramipexol + Pregabalin + pramipexol + pramipexol | Pfizer | Phase 3 | 76 |
| cabergoline + levodopa | Pfizer | Phase 3 | 76 |
| Rotigotine | UCB | Phase 3 | 74 |
| Neupro® | UCB | Pre-clinical | 20 |
| Rotigotine Nasal Spray | UCB | Phase 2 | 49 |
| Rotigotine | UCB | Phase 3 | 74 |
| Levetiracetam (Keppra) | UCB | Phase 2 | 49 |
| Rotigotine + Placebo | UCB | Approved | 82 |
| Rotigotine | UCB | Phase 2 | 49 |
| Rotigotine | UCB | Phase 3 | 74 |